{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:50:47Z","timestamp":1771689047465,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Health care utilisation ('claims') databases contain information about millions of patients and are an important source of information for a variety of study types. However, they typically do not contain information about disease severity. The goal of the present study was to develop a health care claims index for rheumatoid arthritis (RA) severity using a previously developed medical records-based index for RA severity (RA medical records-based index of severity [RARBIS]).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The study population consisted of 120 patients from the Veteran's Administration (VA) Health System. We previously demonstrated the construct validity of the RARBIS and established its convergent validity with the Disease Activity Score (DAS28). Potential claims-based indicators were entered into a linear regression model as independent variables and the RARBIS as the dependent variable. The claims-based index for RA severity (CIRAS) was created using the coefficients from models with the highest coefficient of determination (R<jats:sup>2<\/jats:sup>) values selected by automated modelling procedures. To compare our claims-based index with our medical records-based index, we examined the correlation between the CIRAS and the RARBIS using Spearman non-parametric tests.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The forward selection models yielded the highest model R<jats:sup>2<\/jats:sup> for both the RARBIS with medications (R<jats:sup>2<\/jats:sup> = 0.31) and the RARBIS without medications (R<jats:sup>2<\/jats:sup> = 0.26). Components of the CIRAS included tests for inflammatory markers, number of chemistry panels and platelet counts ordered, rheumatoid factor, the number of rehabilitation and rheumatology visits, and Felty's syndrome diagnosis. The CIRAS demonstrated moderate correlations with the RARBIS with medication and the RARBIS without medication sub-scales.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>We developed the CIRAS that showed moderate correlations with a previously validated records-based index of severity. The CIRAS may serve as a potentially important tool in adjusting for RA severity in pharmacoepidemiology studies of RA treatment and complications using health care utilisation data.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar2482","type":"journal-article","created":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T18:13:34Z","timestamp":1219342414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study"],"prefix":"10.1186","volume":"10","author":[{"given":"Gladys","family":"Ting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Scranton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey N","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"key":"2331_CR1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2294-2300. 10.1002\/art.10529.","journal-title":"Arthritis Rheum"},{"key":"2331_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/03009740410005845","volume":"33","author":"S Sihvonen","year":"2004","unstructured":"Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A: Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004, 33: 221-227. 10.1080\/03009740410005845.","journal-title":"Scand J Rheumatol"},{"key":"2331_CR3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 Patients. Arthritis Rheum. 2004, 50: 1740-1751. 10.1002\/art.20311.","journal-title":"Arthritis Rheum"},{"key":"2331_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","volume":"85","author":"G Gridley","year":"1993","unstructured":"Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993, 85: 307-311. 10.1093\/jnci\/85.4.307.","journal-title":"J Natl Cancer Inst"},{"key":"2331_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056\/NEJMoa011110.","journal-title":"N Engl J Med"},{"key":"2331_CR6","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285. 10.1001\/jama.295.19.2275.","journal-title":"JAMA"},{"key":"2331_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/ard.2004.030528","volume":"64","author":"P Geborek","year":"2005","unstructured":"Geborek P, Bladstr\u00f6m A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005, 64: 699-703. 10.1136\/ard.2004.030528.","journal-title":"Ann Rheum Dis"},{"key":"2331_CR8","first-page":"1018","volume":"33","author":"J Jarand","year":"2006","unstructured":"Jarand J, Zochodne DW, Martin LO, Voll C: Neurological complications of infliximab. J Rheumatol. 2006, 33: 1018-1020.","journal-title":"J Rheumatol"},{"key":"2331_CR9","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44: 2862-2869. 10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W.","journal-title":"Arthritis Rheum"},{"key":"2331_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.47.12.988","volume":"47","author":"AJ Silman","year":"1988","unstructured":"Silman AJ, Petrie J, Hazleman B, Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988, 47: 988-992. 10.1136\/ard.47.12.988.","journal-title":"Ann Rheum Dis"},{"key":"2331_CR11","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1002\/art.10679","volume":"46","author":"SL Brown","year":"2002","unstructured":"Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46: 3151-3158. 10.1002\/art.10679.","journal-title":"Arthritis Rheum"},{"key":"2331_CR12","first-page":"335","volume":"7","author":"AM Walker","year":"1996","unstructured":"Walker AM: Confounding by indication. Epidemiology. 1996, 7: 335-336.","journal-title":"Epidemiology"},{"key":"2331_CR13","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.22056","volume":"54","author":"S Setoguchi","year":"2006","unstructured":"Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S: Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 2757-2764. 10.1002\/art.22056.","journal-title":"Arthritis Rheum"},{"key":"2331_CR14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 1754-1764. 10.1002\/art.22600.","journal-title":"Arthritis Rheum"},{"key":"2331_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.20925","volume":"53","author":"D Cabral","year":"2005","unstructured":"Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH: Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum. 2005, 53: 61-66. 10.1002\/art.20925.","journal-title":"Arthritis Rheum"},{"key":"2331_CR16","first-page":"1679","volume":"32","author":"G Ting","year":"2005","unstructured":"Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH: Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol. 2005, 32: 1679-1687.","journal-title":"J Rheumatol"},{"key":"2331_CR17","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar1921","volume":"8","author":"M Sato","year":"2006","unstructured":"Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, Ting G, Shadick NA, Solomon DH: The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006, 8: R57-10.1186\/ar1921.","journal-title":"Arthritis Res Ther"},{"key":"2331_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45: 613-619. 10.1016\/0895-4356(92)90133-8.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 4","key":"2331_CR19","first-page":"AS36","volume":"33","author":"RM Poses","year":"1995","unstructured":"Poses RM, Smith WR, McClish DK, Anthony M: Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data?. Med Care. 1995, 33 (Suppl 4): AS36-46.","journal-title":"Med Care"},{"key":"2331_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/00005373-199810000-00032","volume":"45","author":"R Rutledge","year":"1998","unstructured":"Rutledge R, Osler T: The ICD-9-based illness severity score: a new model that outperforms both DRG and APR-DRG as predictors of survival and resource utilization. J Trauma. 1998, 45: 791-799.","journal-title":"J Trauma"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2482.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar2482\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2482.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:33:10Z","timestamp":1728383590000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar2482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,8]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1186\/ar2482","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,21]]},"assertion":[{"value":"12 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R95"}}